Skip to main content

The concept of precision medicine as proposed by DC-ren is also of great interest to SMEs and other academic institutions. In order to allow collaborations, we established the concept of “DC-ren associated studies”. The DC-ren team was approached by Nordic Bioscience® (based in Herlev, Denmark), a company focusing amongst others on biomarkers of extracellular matrix turnover, a pathomechanism of great interest in the context of drug response and DKD progression. The DC-ren consortium and Nordic Bioscience agreed to collaborate on a project looking at the association of novel extracellular matrix turnover biomarkers with cardiorenal outcome and mortality as well as treatment response in patients with diabetes mellitus type 2.

EU Flag DC-ren | Medical University Innsbruck

DC-ren has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848011.